跳到正文
原文
BioPharma Dive· Ben Fidler·· 14 天前精选AI 评分65

本周图表:三家药企的药物上市表现

This week in charts: 3 drug launches Wall Street is watching

AI 导读

本周,Novo 的 Wegovy 药片销售超出预期,Madrigal 的 Rezdiffra 成为重磅药物,Axsome 的 Auvelity 销售增长缓慢。

推荐理由

详细报道了三家药企的药物上市表现,为投资者提供决策参考。

正文 · AI 翻译

译文尚不完整,完整内容请切换到原文。

这是 BioPharma Dive 用数据可视化回顾整个行业动态系列报道的最新一期。今天,我们将看看投资者对本周季度财报中介绍的三款新药的反应。

诺和诺德在减肥药物领域已经失去了领先地位,与主要竞争对手礼来公司相比,表现不佳。但在本周披露的关键销售数据让投资者看到了未来可能更好的迹象。

On Wednesday, Novo revealed that the Wegovy pill — the oral version of the popular obesity medicine bearing the same name — booked 5.39 billion Danish kroner in the third quarter. Equivalent to about $811 million, that figure surpassed the average consensus estimate of 4.96 billion kroner, according to analysts at the firm Jefferies. Overall company sales and profit beat Wall Street’s projections, too. 

The news lifted Novo shares by more than 5%, one of its largest single-day gains this year. Perhaps more notably, though, the Wegovy pill’s sales spike came during the same quarter Lilly’s rival offering, Foundayo, underperformed. Lilly’s drug launched a few months after Novo’s, and isn’t as broadly available yet. But its $184 million in third-quarter sales fell short of Wall Street estimates by $44 million and represented the only blemish for an obesity and diabetes drug franchise that otherwise smashed consensus forecasts. 

The Wegovy pill “continued to outpace” Foundayo and accounted for around 80% of new-to-brand U.S. prescriptions in the third quarter, said Jamey Millar, the head of Novo’s U.S. operations, on a Wednesday earnings call.

诺和诺德希望在美国和国际上继续这种增长。“我不认为这会完全改变现状,”首席执行官 Mike Doustdar 对分析师表示。“我们在美国和国际上的表现如何,不会因为 12 月之后是 1 月而改变。”

该片剂已在七个国家上市。诺和诺德预计到明年年初将有超过 20 个国家可用。

诺和诺德的 Wegovy 片剂在第三季度销售量激增

药物销售额超过了华尔街的预期,此前在上一个财报期间销售低于预期。

Madrigal Pharmaceuticals made history with the 2024 approval of Rezdiffra, the first medication for a liver disease known as metabolic dysfunction-associated steatohepatitis, or “MASH.” Since then, Wall Street has been closely tracking Rezdiffra’s progress, as the drug’s sales trajectory is an important indicator of the demand for MASH drugs. Many investors weren’t convinced Rezdiffra would become a big seller.     

New results disclosed this week, though, show that Rezdiffra sales — which got off to a better-than-anticipated start — are still climbing. In its tenth quarter on the market, the drug officially reached “blockbuster” status, meaning its sales eclipsed $1 billion in a calendar year. Rezdiffra generated $431 million for Madrigal between July and September, and $1.1 billion so far in 2026. The quarterly numbers beat consensus projections by more than $20 million and enabled Madrigal to post a profit for the first time. 

结果“再好不过了”,甚至超出了提高的投资者预期,”Cantor Fitzgerald 分析师 Prakhar Agrawal 在周二的客户报告中写道。

Particularly of note, according to Agrawal, is that more patients have started treatment despite competition in MASH from Novo’s Wegovy. That upswing suggests MASH diagnosis and treatment rates — both of which are still low — could be accelerating. There’s “meaningful room for growth,” he added. 

Madrigal shares initially spiked before changing course on Tuesday, a shift analysts attributed to a whistleblower lawsuit brought forth by a former employee.

Madrigal 的 MASH 药物 Rezdiffra 成为了重磅炸弹

Rezdiffra 在 2026 年前九个月创造了 11 亿美元的销售额。

Five months ago, brain drug developer Axsome Therapeutics saw its market value soar past $12 billion. An April Food and Drug Administration approval had just expanded use of its depression drug Auvelity into Alzheimer’s disease, unlocking what Wall Street believed to be a multibillion-dollar market opportunity. Investors piled into the stock, believing Axsome might be a top buyout target in an already active year for biotech company acquisitions. 

Yet at least so far, Auvelity hasn’t taken off. Sales grew from about $153 million between January and March to $208 million over the last three months, Axsome reported Monday. On a conference call with analysts, Chief Commercial Officer Ari Maizel noted that there’s “little precedent” for a medicine that, like Auvelity, is used to treat symptoms of “agitation” associated with Alzheimer’s.

“这仍然是一个相对较新且正在发展的市场,但我们对迄今为止看到的情况感到非常鼓舞,”Maizel 说,提到了处方数量的增加。

Auvelity 的销售额没有像投资者希望的那样迅速增长

Auvelity 在四月份获得阿尔茨海默病激越批准后的季度销售额(以百万美元计)。

投资者的信心似乎有所减弱。自六月达到峰值以来,Axsome 的股价下跌了三分之一以上。制药公司收购的步伐有所放缓。尽管 Auvelity 最新数据符合市场预期,但该药物的最新推出“比预期的要慢”,William Blair 分析师 Myles Minter 写道。他的同行们中的几位进一步下调了 Axsome 股票的价格目标和 Auvelity 销售预测。

“过去四个月对 Axsome 来说非常艰难,”Leerink Partners 分析师 Marc Goodman 写道。投资者现在“对 Auvelity 的趋势感到相当悲观”。

然而,他和其他人呼吁保持耐心。在第三季度,65 岁以上成年人的处方数量加速增长,他们主要使用 Auvelity 来治疗阿尔茨海默病症状,高管们表示。尽管药物销售额的增长是渐进的,“但这正在发生,”Goodman 断言。

来源:BioPharma Dive · biopharmadive.com